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Abstract Background: A novel estradiol-based combined oral contraceptive (COC) is
currently available in many countries worldwide, including Europe and the
US. Based on previous studies, it is expected that this estradiol-based COC
will have a reduced hepatic effect compared with COCs containing ethinyl-
estradiol with regard to proteins controlling the hemostatic balance.
Objective: The aim of this study was to compare the hemostatic effects of the
estradiol valerate/dienogest COC with a monophasic low-estrogen dose COC
containing ethinylestradiol/levonorgestrel.
Study Design: Healthy women aged 18–50 years were randomized to receive
a COC containing estradiol valerate/dienogest (2 days estradiol valerate 3mg,
5 days estradiol valerate 2mg/dienogest 2mg, 17 days estradiol valerate
2mg/dienogest 3mg, 2 days estradiol valerate 1mg, 2 days placebo) or ethinyl-
estradiol 0.03mg/levonorgestrel 0.15mg in a crossover study design. Women
received each treatment for three cycles, with two washout cycles between
treatments. The primary efficacy variables were the intra-individual absolute
changes in prothrombin fragment 1+ 2 andD-dimer frombaseline to cycle three.
Results: Data from 29 women were assessed. Intra-individual absolute changes
in prothrombin fragment 1 + 2 and D-dimer from baseline to cycle three were
less pronounced with estradiol valerate/dienogest than with ethinylestradiol/
levonorgestrel.
Conclusion: The novel COC containing estradiol valerate/dienogest had
similar or less pronounced effects on hemostatic parameters than ethinyl-
estradiol/levonorgestrel.
Introduction
Combined oral contraceptives (COCs) have
become a widely used form of birth control due to
their contraceptive efficacy and good tolerability
profile. COCs have undergone considerable de-
velopment since their introduction in the 1960s,
including reductions in the dose of synthetic
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estrogen (i.e. ethinylestradiol)[1-3] and the incorpora-
tion of progestogens with more favorable clinical
profiles.[4]
However, COCs that contain ethinylestradiol
and its prodrug mestranol have been associated
with a slight increased risk of cardiovascular events,
such as venous thromboembolism.[5,6] Neverthe-
less, these events occur rarely, and the increased
risk of thromboembolism during pregnancy and
the puerperium must be considered.[7] Risk factors
for thrombotic or thromboembolic events include
age, smoking, a positive family history, genetic
thrombophilias (e.g. Factor V Leiden mutation),
obesity, dyslipoproteinemia, hypertension,migraine,
valvular heart disease, atrial fibrillation, prolonged
immobilization, major surgery, any surgery to the
legs, and major trauma.[8]
It is well established that the hormonal com-
ponents of COCs have various effects on hemo-
stasis. Moreover, the adverse effects on hemostatic
variables are most likely to be influenced by the
estrogen type and dose rather than the type of
progestogen used. Although hemostatic surrogate
parameters are not predictive of the occurrence of
thromboembolic events, their evaluation is part
of the development process of COCs. Epidemio-
logic studies are required to evaluate the incidence
of venous and arterial thromboembolism in COC
users, since these events are so rare that they cannot
be accurately assessed in phase III clinical studies.
Several attempts to develop COCs containing
17b-estradiol as the estrogenic component have
been made based on the hope that this will
(i) improve their tolerability and acceptability;
and (ii) broaden the choice for COC users.[9-21]
To prevent the poor cycle control that has been
observed with previous 17b-estradiol-containing
COCs,[11,16-19,21] a novel COC containing estradiol
valerate (1mg estradiol valerate corresponds to
0.76mg 17b-estradiol) and dienogest with a fixed
estrogen step-down/progestogen step-up dynam-
ic dosing regimen has been developed. Estradiol
valerate/dienogest has been shown to be associated
with reliable contraceptive efficacy[22,23] and good
cycle control.[24] Moreover, 17b-estradiol levels
have been shown to be stable throughout the cy-
cle, with estrogen levels remaining comparable
with those during the early follicular phase.[25]
Based on studies that have evaluated the effect
of 17b-estradiol versus ethinylestradiol on hepatic
protein synthesis,[26-29] it is expected that estra-
diol valerate/dienogest will have a considerably
reduced hepatic effect compared with COCs con-
taining ethinylestradiol with regard to proteins
controlling the hemostatic balance.
The current study was conducted to quantify
the effects of estradiol valerate/dienogest on var-
ious key parameters of the coagulation system,
indicating changes in the pro-coagulatory, anti-
coagulatory, and fibrinolytic activity. A COC
containing ethinylestradiol 0.03mg/levonorges-
trel 0.15mg was used as the comparator COC.
Methods
Study Design
This was a crossover, active-treatment-controlled,
randomized, open-label, single-center study con-
ducted between April 2006 and May 2007 (pro-
tocol number 310122).[30] The design of the study
was selected in adherence to the requirements of
the European Medicines Agency Committee for
Medicinal Products for Human Use (CHMP)
[EMEA/CPMP/EWP/519/98 Rev 1].[31] The stu-
dy protocol was approved by the local Ethics
Committee in the Netherlands. The study was
conducted in accordance with the ethical principles
that have their origin in the Declaration of Hel-
sinki and the International Conference on Har-
monization – Good Clinical Practice. Written
informed consent was obtained from all study
participants prior to entry into the study.
Study Population
Healthy women aged 18–50 years who required
contraception were eligible for inclusion. Exclusion
criteria included the following: pregnancy; lacta-
tion; occurrence of less than three menstrual cy-
cles following childbirth, abortion, or lactation;
known hypersensitivity to any ingredients of the
study drugs; known diseases or conditions that
might result in the altered absorption, excessive
accumulation, impaired metabolism, or altered
excretion of the study medication; any known
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severe systemic disease that might interfere with
the conduct of the study or interpretation of the
results; uncontrolled thyroid disorders; clinically
significant depression; abnormal clinically signifi-
cant findings that might worsen under hormonal
treatment; laboratory values outside inclusion
ranges at screening; operations scheduled during
the study period; liver disease; vascular and meta-
bolic diseases, or factors that predispose to vas-
cular and metabolic diseases; sickle-cell anemia;
known or suspected malignant or premalignant
disease; alcohol, drug, or medicine abuse; use of
prohibited concomitant medication; use of sex
hormones prior to the start of treatment (includ-
ing oral, transdermal, intrauterine, or intravaginal
administration within two cycles prior to the start
of treatment; implants within 2 months prior to the
study; long-acting progestogens within 6 months
prior to visit 1); and a body mass index >30kg/m2.
Cigarette consumption of up to 10 per day was
permitted in women aged 18–30 years, while
women aged >30 years were required to be non-
smokers. The use of additional sex steroids was
prohibited.
Study Treatment
The study utilized a crossover design (figure 1).
All women were randomized to receive three cy-
cles (84 consecutive days) of estradiol valerate/
dienogest (estradiol valerate 3mg for 2 days,
estradiol valerate 2mg/dienogest 2mg for 5 days,
estradiol valerate 2mg/dienogest 3mg for 17 days,
estradiol valerate 1mg for 2 days, and placebo for
2 days) and three cycles (84 consecutive days) of
ethinylestradiol/levonorgestrel (ethinylestradiol
0.03mg/levonorgestrel 0.15mg for 21 days and
placebo for 7 days). Both treatment periods were
preceded and separated by a washout period of
two cycles.
Randomization was performed in blocks using a
computer-generated list (obtained from the Central
Randomization Service of Bayer HealthCare Phar-
maceuticals). Women were instructed to start tablet
intake on the first day of menstrual bleeding. Tablet
intake was recorded using diary cards.
Women were to take any missed tablets as soon
as remembered, at the latest with the next admin-





























Fig. 1. Design of the crossover study. E2V/DNG= estradiol valerate/dienogest; EE/LNG = ethinylestradiol/levonorgestrel; EOT = end of
treatment; SOT = start of treatment (first day of bleeding); V1= screening visit; V2 =baseline (days 15–21 of the cycle); V3 =end of treatment
period 1 (end of treatment cycle 3) [E2V/DNG = treatment days 74–80; EE/LNG = treatment days 71–77]; V4= end of washout cycle 1 (days
15–21 of the cycle); V5 =end of washout cycle 2 (days 15–21 of the cycle)/baseline for treatment period 2; V6 =end of treatment period 2 (end
of treatment cycle 6) [E2V/DNG = treatment days 158–164; EE/LNG = treatment days 155–161]; V7 = up to 2 weeks after the end of treatment,
but at least 2 days after the end of the withdrawal bleeding that followed treatment cycle 6.
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tablet was missed, only the most recently missed
tablet (i.e. the one of the immediately preceding
day) was to be taken as soon as remembered.
Study Assessments
Citrated (0.11mmol/L) blood specimens were
taken with minimal stasis at baseline (visit 2), at
the end of each washout cycle (visits 4 and 5), and
at the end of the estrogen/progestogen phase of
treatment cycle three (visit 3) and treatment cycle
six (visit 6). Specimens were collected at least
2 hours after the previous meal. To minimize the
variability of the concentration of high molecular
weight blood constituents due to variations in
intravascular blood volume, subjects were asked
to rest in a supine or sitting position for at least
10 minutes prior to blood collection. The vein
was then obstructed for a short time and then
released prior to punction for blood collection.
For the preparation of platelet-free citrated
plasma (required for the measurement of several
hemostatic parameters), samples were centrifuged
twice at a force of ‡2500g for 15minutes at ambient
temperature. For serum preparation (required
for the measurement of sex hormone-binding
globulin [SHBG]), samples were centrifuged at a
force of ‡1200 g for 15 minutes at ambient tem-
perature. Samples were clearly labeled and all
necessary transport and storage of blood were
performed under appropriate conditions.
The hemostatic markers that were assessed are
shown in table I.
Primary Target Parameters
The primary target parameters were the intra-
individual absolute changes from baseline in
thrombin and fibrin turnover, assessed using the
markers prothrombin fragment 1+ 2 and D-dimer,
after three treatment cycles with estradiol valerate/
dienogest and ethinylestradiol/levonorgestrel.
Secondary Target Parameters
The secondary target parameters were the intra-
individual absolute changes from baseline in
(pro)coagulatory parameters, anti-coagulatory
parameters, thrombin and fibrin turnover, and
SHBG levels, after three treatment cycles with
estradiol valerate/dienogest and ethinylestradiol/
levonorgestrel.
Safety
Safety was evaluated by adverse event record-
ing throughout the study, and by general physical
and gynecologic examinations (including vital signs,
breast palpation, transvaginal ultrasonography,
and cytological cervix smear) performed at screen-
ing (visit 1) and within 2 weeks after stopping study
treatment (visit 7).
Statistics
Analyses of all target parameters and safety
parameters were based on the full analysis set
(FAS). This included all women who received at
least one dose of treatment, and for whom data
from the treatment phase were available.
Thirty women were planned to be randomized
and, assuming a withdrawal rate of 30% (includ-
ing all major protocol deviations), approximately
Table I. Hemostatic markers assessed [product name; manu-
facturer]
Thrombin and fibrin turnover (activation markers)
Prothrombin fragment 1 +2 [Enzygnost F1 + 2 micro;
Dade-Behring, Marburg, Germany]
D-dimer [Asserachrom D-Dimer; Roche, Rotkreuz, Switzerland]
Factor II (prothrombin) activity (IIc) [Dade-Behring, Marburg,
Germany]
Pro-coagulatory parameters
Fibrinogen [Dade-Behring, Marburg, Germany]
Factor VII activity (VIIc) [Dade-Behring, Marburg, Germany]
Factor VIII activity (VIIIc) [Dade-Behring, Marburg, Germany]
Anti-coagulatory parameters
Antithrombin III activity [COAMATIC LR; Haemochrom Diagnostica
GmbH, Essen, Germany]
Protein C activity [COAMTIC Protein C; Haemochrom Diagnostica
GmbH, Essen, Germany]
Protein S activity [Protein S ELISA; Haemochrom Diagnostica
GmbH, Essen, Germany]
APC resistance based on activated partial thromboplastin time
[COATEST APC Resistance; Haemochrom Diagnostica GmbH,
Essen, Germany]
APC sensitivity ratio (Rosing test)[32] determined according to a
modified protocol based on the original method kindly provided
by Professor Jan Rosing, University of Maastricht, Maastricht,
the Netherlands
APC =activated protein C.
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20 women were planned to be included in the per-
protocol set analysis. Since this sample size is
standard for metabolic studies and based on
regulatory requirements, no power calculation
was considered necessary.
For each primary target variable, the absolute
change from the corresponding baseline value after
treatment over three cycles (i.e. value at baseline
[visit 2] or after the washout cycle two [visit 5] of the
respective treatment period) was to be calculated
and analyzed using ANOVA. The significance level
of a nominal 5% was adjusted to 2.5% for multiple
testing using the Bonferroni method.
For each hemostatic marker listed as a second-
ary variable, a post hoc explorative analysis was
performed. The relative change from baseline to
cycle three was determined and an ANOVA with a
comparison-wise significance level of 5% was used
to test the differences between the two treatments.
Results
Subject Disposition
A total of 34 women were screened according
to the selection criteria for inclusion in the study.
Of these, 32 womenwere deemed eligible for treat-
ment and were randomized to estradiol valerate/
dienogest (n= 16) or ethinylestradiol/levonorgestrel
(n = 16). A total of 29 women received at least one
unit of any study drugs dependent on their as-
signment to one of the two treatment sequences
and were part of the FAS. In total, 26 women
completed three cycles with the estradiol valerate/
dienogest treatment and 27women completed three
cycles with the ethinylestradiol/levonorgestrel treat-
ment. The flow of women through the study is
shown in figure 2.
The mean age of women in the FAS (n = 29)
was 27.4 years, and the mean body mass index
was 21.7 kg/m2; the majority (n = 27; 93.1%) of
women in the FAS were Caucasian and non-
smokers (n = 22; 75.9%). Fifteen (51.7%) women
were using oral contraceptives before the study
washout period. Nine (31.0%) women reported
no prior use of any contraceptive method.
According to diary records, 22 (81.5%) and
21 (72.4%) women took all the required tablets in the
estradiol valerate/dienogest and ethinylestradiol/
levonorgestrel treatment phases, respectively. There
were, respectively, one woman (3.7%) and three
women (10.3%) with major treatment deviations
in the estradiol valerate/dienogest and ethinyl-
estradiol/levonorgestrel treatment phases. The
frequency of minor protocol deviations was com-
parable under both study treatments, namely four
(14.8%) women in the estradiol valerate/dienogest




Thrombin and Fibrin Turnover (Activation Markers)
During treatment with estradiol valerate/
dienogest, no intra-individual change was seen
in the levels of prothrombin 1 + 2, whereas a slight
increase was observed with ethinylestradiol/
levonorgestrel, although mean levels in both treat-
ment groups remained in the reference interval
(table II). The differences between the two treat-
ments were not statistically significant. Mean
baseline levels of D-dimer were almost compar-
able at the start of each treatment period with the
respective study treatment. A significantly (p= 0.01;
95%CI-217.22,-11.77) smaller increase inD-dimer
levels in the estradiol valerate/dienogest group
(from 203.0 – 94.1 ng/mL to 237.4 – 101.6 ng/mL)
than in the ethinylestradiol/levonorgestrel group
(from 201.8 – 73.5 ng/mL to 352.6 – 217.8 ng/mL)
was observed, but mean levels in both groups also
remained in the reference interval. The intra-
individual relative change was 37.3%– 69.3% and
88.1%– 99.3% for estradiol valerate/dienogest and
ethinylestradiol/levonorgestrel, respectively (table II).
Secondary Target Parameters
Thrombin and Fibrin Turnover (Activation Markers)
Following treatment in both groups, pro-
thrombin levels were above the normal range;
however, intra-individual increases were more
pronounced in the ethinylestradiol/levonorgestrel
group (table II).
Pro-Coagulatory Parameters
Changes in pro-coagulatory markers with
treatment were generally less pronounced with
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estradiol valerate/dienogest than with ethinyl-
estradiol/levonorgestrel (table III). Mean fibrino-
gen levels were elevated above the normal range
in both treatment groups, although the mean in-
tra-individual increase was greater in the ethinyl-
estradiol/levonorgestrel group (table III). Mean
levels of factor VII activity increased minimally
in the estradiol valerate/dienogest group and
slightly more pronounced in the ethinylestradiol/
levonorgestrel group; however, mean levels re-
mained within the reference range. Almost no
changes in the mean levels of factor VIII were
observed in either treatment group (table III).
Anti-Coagulatory Parameters
Only minor changes were observed in most anti-
coagulatory markers. The mean levels of anti-
thrombin III activity, protein C activity, protein S
activity, and activated protein C (APC) resistance
remained generally stable and within the refer-
ence range in both treatment groups (table III).
However, APC sensitivity ratio levels were slightly
above the proposed reference range[32] in the
ethinylestradiol/levonorgestrel group. The difference
between the two treatments in mean individual
relative change from baseline to cycle three was





Study discontinued before start
of treatment: n = 2
Withdrawal of consent: 2
Treatment period 1: E2V/DNG
n = 14
Treatment period 1 completed
n = 14
Treatment period 2: EE/LNG
n = 14
Treatment period 2 completed
n = 14
Treatment period 1: EE/LNG
n = 15






Treatment period 2: E2V/DNG
n = 13
Treatment period 2 completed
n = 12
Treatment discontinued: n = 1
Withdrawal of consent: 1
Study discontinued before start
of treatment: n = 1




Screening failures: n = 2
Selection criteria not met: 1
Other (extended cycle duration): 1
Treatment discontinued: n = 2
Withdrawal of consent: 1
AEs (painful breasts, GI disorder,




Fig. 2. Study flow chart showing the number of women screened, randomized, and completing treatment. For sequence A, full analysis set
(FAS) was n= 14, per-protocol set (PPS) was n =13 (one volunteer from FAS with major protocol deviation[s]). For sequence B, FAS was
n= 15, PPS was n =11 (four volunteers from FAS with major protocol deviation[s]). AEs = adverse events; E2V/DNG= estradiol valerate/
dienogest; EE/LNG =ethinylestradiol/levonorgestrel; GI =gastrointestinal.
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As is common with any population, at baseline,
a small and comparable proportion of women with
both treatments had values outside the reference
ranges for the parametersmeasured.Although there
were no statistical differences between treatments
in the majority of parameters measured, at cycle
three, the proportion of women who had values
outside of the reference range was higher with
ethinylestradiol/levonorgestrel treatment than with
estradiol valerate/dienogest treatment.
Sex-Hormone Binding Globulin (SHBG) Levels
Following three treatment cycles, mean SHBG
concentrations increased by comparable levels in
each treatment group (from 48.80 – 19.34 nmol/L
at baseline to 72.61 – 27.95 nmol/L at cycle three
with estradiol valerate/dienogest, and from
51.73– 21.27 nmol/L to 72.60– 30.12 nmol/L with
ethinylestradiol/levonorgestrel). At the end of the
respective treatments, there were two women
with increased values and one woman with a de-
creased value that were outside of the reference
range, in each of the two treatment groups.
Safety
Fifty-one adverse events were reported by 20
women (74.1%) in the estradiol valerate/dienogest
group, and 61 adverse events by 20 women
(69.0%) in the ethinylestradiol/levonorgestrel group.
The most commonly reported adverse events in
the estradiol valerate/dienogest and ethinylestradiol/
levonorgestrel groups were headache (11 cases
in 6 women [22.2%]; and 14 cases in 11 women
[37.9%], respectively) and nasopharyngitis (5 cases
in 5 women [18.5%]; and 6 cases in 5 women
[17.2%], respectively [table IV]).
No adverse events were considered definitely
or probably related to either study drug. More-
over, there were no serious adverse events or
deaths reported during the study.
The mean systolic and diastolic blood pressure
values were generally stable throughout the study
visits. The results of the cervical smear screening
were normal for all but one woman (3.4%) who
had an abnormal result (cervical dysplasia) at
final examination. There were no positive results
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Discussion
The findings from this study show that estradiol
valerate/dienogest has a similar or less of an impact
on hemostatic parameters than a monophasic
COC containing ethinylestradiol/levonorgestrel
over three cycles of treatment. This was manifested
in a significantly smaller increase in D-dimer lev-
els (37% vs 88% for estradiol valerate/dienogest
and ethinylestradiol/levonorgestrel, respectively)
and by less pronounced increases in the levels
of prothrombin and fibrinogen. The APC resis-
tance, as measured by the partial thromboplastin
time, remained unchanged in both groups, where-
as themeanAPC sensitivity ratio (measured using
the Rosing test[32]) showed a distinctly and sta-
tistically significant greater increase in the ethinyl-
estradiol/levonorgestrel group. It should be noted
that both tests reflect the protein C mediated anti-
coagulatory activity in plasma, but the Rosing test
shows a higher sensitivity towards concentration
changes of the proteins involved. Although no sig-
nificant differences between treatments were ob-
served in the majority of parameters measured, at
cycle three, the proportion of women who had sev-
eral values outside of the reference range was higher
with ethinylestradiol/levonorgestrel treatment
than with estradiol valerate/dienogest treatment.
It is generally well accepted that the influence
of COCs on coagulation and fibrinolysis depends
mainly on the estrogen component of the regi-
men. The reduced impact of estradiol valerate/
dienogest on hemostatic parameters observed in
the current study is probably due to the inclusion
of estradiol valerate instead of ethinylestradiol as
the estrogenic component. Estradiol valerate is
considerably less potent than ethinylestradiol in
terms of hepatic protein synthesis induction, as
demonstrated in clinical studies assessing SHBG,
angiotensinogen, and hemostatic parameters.[26-29]
However, changes observed with COCs reflect
not only influences of the estrogen component,
but also those of the progestogen component;
indeed, progestogen can affect the binding of
testosterone or cortisol to transport proteins[33]
and the clearance time from serum.[34]
The findings of the current study are also











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































166 Klipping et al.
ª 2011 Klipping et al., publisher and licensee Adis Data Information BV. Drugs R D 2011; 11 (2)
metabolic effects of estradiol valerate/dienogest
with a triphasic regimen of ethinylestradiol/
levonorgestrel.[35] In the comparative study with
triphasic ethinylestradiol/levonorgestrel, levels of
factors associated with activation of coagulation
increased slightly with both study preparations,
but generally remained well within the normal
reference range.Observed changes were consistently
less pronounced with estradiol valerate/dienogest
relative to ethinylestradiol/levonorgestrel. Further-
more, increases in the levels of SHBG were ob-
served in both groups, with increases being less
marked in women who received estradiol valerate/
dienogest compared with women who received
ethinylestradiol/levonorgestrel. Despite the fact
that levels of SHBG increased in the estradiol
valerate/dienogest group, mean levels remained
within the normal range, whereas in the ethinyl-
estradiol/levonorgestrel group, the mean levels
of SHBG increased to exceed the normal range.[35]
It is, however, questionable whether measuring
SHBG levels is the most appropriate way of as-
sessing estrogen-induced effects of COCs. SHBG
levels increase with use of COCs, with the ob-
served net effect resulting from effects exerted
by both components. Estrogen increases SHBG
levels in a dose-dependent fashion. Moreover, at
the dose required to produce similar effects on
follicle-stimulating hormone suppression, ethinyl-
estradiol increases levels of SHBG to a greater
extent than 17b-estradiol.[28] SHBG levels are
decreased by androgens and some progestogens
with partial androgenic activity, including levo-
norgestrel. In contrast, dienogest, drospirenone,
and cyprotenone acetate do not counteract the
estrogen-induced increases of SHBG.[34] Never-
theless, in the current study, increases in SHBG
were more pronounced with ethinylestradiol/
levonorgestrel than with estradiol valerate/
dienogest. This is possibly consistent with the in-
clusion of estradiol valerate instead of ethinyl-
estradiol as the estrogenic component, with estra-
diol valerate being less potent than ethinylestradiol
in terms of hepatic protein synthesis induction.[29]
A prudent approach is necessary when attempt-
ing to interpret surrogate parameters for clinical
outcomes. Hemostaseologic surrogate parameters
have not been proven to capture the modifying
effect of COCs on the risk of thromboembolic
events.[36-38] Biomarkers and surrogate endpoints
have important roles to play in exploratory re-
search and development trials, but cannot be used
clinically until validated, no matter how intuiti-
vely appealing the biomarker may be.[31,37] For a
surrogate endpoint to be an effective substitute
for the clinical outcome, effects of the inter-
vention on the surrogate must reliably predict the
overall effect on the clinical outcome. However,
the validity of a surrogate endpoint has rarely
been rigorously established.[39]
Therefore, it is important that caution is ap-
plied in the interpretation of the observed differ-
ences in surrogate hemostatic parameters between
estradiol valerate/dienogest and ethinylestradiol/
levonorgestrel since these parameters have not
been proven to be predictive of the occurrence of
actual clinical events. Nevertheless, the current
study is a useful comparison of the impact on hemo-
static parameters of a novel dynamically dosed
COC containing estradiol valerate/dienogest with
that of the established COC regimen containing
ethinylestradiol/levonorgestrel.
As such, a COC containing estradiol valerate
at dosages of 1–3mg (as used in the current study)
may induce less estrogen-related responses in the
liver than currently available ethinylestradiol-
containing COCs. However, further clinical and
epidemiologic studies will be needed to confirm
whether this translates into better clinical out-
comes over the long term.
Since the estradiol valerate/dienogest COC is
new to the market, epidemiologic study data on
cardiovascular safety are currently not available.
Table IV. Most commonly reported adverse events (occurring
in >10% of women; full analysis set)
Adverse event Number of women (%)
E2V/DNG (n= 27) EE/LNG (n= 29)
Headache 6 (22.2) 11 (37.9)
Nasopharyngitis 5 (18.5) 5 (17.2)
Gastrointestinal disorder 2 (7.4) 4 (13.8)
Dysmenorrhea 3 (11.1) 4 (13.8)
Nausea NA 3 (10.3)
E2V/DNG= estradiol valerate/dienogest; EE/LNG = ethinylestradiol/
levonorgestrel; NA= not applicable.
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Moreover, the information from clinical trials is
limited, based on the rarity of events such as venous
thromboembolism and the limited number of
patients investigated in phase III trials. Therefore,
it is reassuring that estradiol valerate/dienogest
has a similar or less pronounced hemostatic
impact than the well established monophasic
ethinylestradiol/levonorgestrel, a COC that has
been comprehensively studied and extensively
marketed. Furthermore, results of a double-blind,
randomized study suggest that a monophasic
COC combining nomegestrol acetate 2.5mg with
17b-estradiol 1.5mg might have less of an impact
on hemostatic parameters compared with levo-
norgestrel 0.10mg/ethinylestradiol 0.02mg.[40] The
overall magnitude of changes in hemostatic pa-
rameters is comparable with those observed with
estradiol valerate/dienogest in the current study
as shown, for example, by a similar increase in
SHBG and by similarly less pronounced increases
in prothrombin fragment 1 + 2 and fibrinogen
and thrombin generation (determined either by
the APC sensitivity ratio[32] or by APC resistance
as measured by the endogenous thrombin gen-
eration method).[40,41] This suggests that COCs
comprising either 17b-estradiol or estradiol
valerate in equimolar doses may have very similar
effects on hemostatic parameters.
It is possible that lower doses of ethinyl-
estradiol (e.g. 0.02mg) may have reduced hemo-
static effects compared with COCs containing
0.03mg of ethinylestradiol, such as the comparator
used in our study.[42-45] However, whether the im-
pact on hemostatic effects is further reduced with
even lower doses of ethinylestradiol than 0.02mg,
down to 0.015mg, may be questionable,[46] and
may also be associated with increased bleeding
irregularities; overall incidences of breakthrough
bleeding and/or spotting of 21%[1] and 29%[47]
with 0.015mg ethinylestradiol have been reported.
An international prospective, controlled, non-
interventional cohort active surveillance study
(INAS-SCORE [International Active Surveillance
Study–Safety of Contraceptives: Role of Estro-
gens]), which is currently underway, was designed
to assess the risks of short- and long-term use of
estradiol valerate/dienogest and of established
COCs in a study population that is representative
of actual users of the individual preparations. A
total of 50 000 new users of a COC (starters or
switchers) will be followed-up over a 3- to 5-year
period to allow documentation of approximately
150 000 women-years. The main clinical out-
comes of interest for the short- and long-term
follow-up are cardiovascular events, primarily
deep venous thrombosis, pulmonary embolism,
acute myocardial infarction, and cerebrovascular
accidents.
In the current study, there were no safety
concerns raised with estradiol valerate/dienogest,
and both study treatments were similarly well
tolerated. None of the adverse events during the
study were rated as serious and only three adverse
events in one subject led to premature study dis-
continuation in the ethinylestradiol/levonorgestrel
group. Exposure to either of the study treatments
was not associated with severe, rare side effects of
COCs; there were no cases of venous or arterial
thromboembolism reported.
Conclusion
In conclusion, a dynamically dosed estrogen
step-down/progestogen step-up estradiol valerate/
dienogest COC regimen had a minimal impact on
hemostatic parameters and was well tolerated.
Findings in both treatment groups support a
positive benefit-risk profile of these COCs.
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